NASDAQ : CVKD
Cadrenal Therapeutics, Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 0.985 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 3.51M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 3.51M |
| Enterprise Value | 1.13M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 3.57M |
| Shares Outstanding | 3.57M |
| Shares Change (YoY) | +44.92% |
| Shares Change (QoQ) | +21.00% |
| Owned by Insiders (%) | 9.73% |
| Owned by Institutions (%) | 10.41% |
| Float | 3.22M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.86 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 3.73 |
| Quick Ratio | 3.39 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -275.16% |
| Return on Assets (ROA) | -125.93% |
| Return on Invested Capital (ROIC) | -173.61% |
| Return on Capital Employed (ROCE) | -284.81% |
| Weighted Average Cost of Capital (WACC) | 14.98% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.31M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.95 |
| 52-Week Price Change | -92.34% |
| 50-Day Moving Average | 1.14 |
| 200-Day Moving Average | 3.94 |
| Relative Strength Index (RSI) | 45.06 |
| Average Volume (20 Days) | 201,284 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 281,405 |
| Short Previous Month | 105,945 |
| Short % of Shares Out | 7.89% |
| Short % of Float | 8.74% |
| Short Ratio (days to cover) | 1.37 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -11.65M |
| Pretax Income | -11.54M |
| Net Income | -11.54M |
| EBITDA | -11.65M |
| EBIT | -11.65M |
| Earnings Per Share (EPS) | -$4.86 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 2.39M |
| Total Debt | n/a |
| Net Cash | 2.39M |
| Net Cash Per Share | $0.67 |
| Equity (Book Value) | 4.09M |
| Book Value Per Share | 1.32 |
| Working Capital | 4.09M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.16M |
| Capital Expenditures | -1,853 |
| Depreciation & Amortization | 2,015 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.16M |
| FCF Per Share | -$2.85 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -44.92% |
| Shareholder Yield | -44.92% |
| Earnings Yield | -493.86% |
| FCF Yield | -289.25% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $14.00 |
| Price Target Difference | 1,321.32% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Aug 20, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:15 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |